<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ACOR</title>
	<atom:link href="http://www.stockbloghub.com/tag/acor/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ACOR) Company News for October 6, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/10/06/acor-company-news-for-october-6-2011-corporate-summary/84712</link>
		<comments>http://www.stockbloghub.com/2011/10/06/acor-company-news-for-october-6-2011-corporate-summary/84712#comments</comments>
		<pubDate>Thu, 06 Oct 2011 17:43:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Acuity Brands Inc.]]></category>
		<category><![CDATA[AYI]]></category>
		<category><![CDATA[CBEY]]></category>
		<category><![CDATA[Cbeyond Inc]]></category>
		<category><![CDATA[CBS]]></category>
		<category><![CDATA[CBS Corporation]]></category>
		<category><![CDATA[CTC Media Inc]]></category>
		<category><![CDATA[CTCM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MON]]></category>
		<category><![CDATA[Monsanto Company]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84712</guid>
		<description><![CDATA[•    Monsanto Co. (NYSE:MON) reported its fiscal fourth-quarter loss of $0.22 cents a share, better than the Zacks Consensus Estimate of a loss of $0.27. Revenues rose 15.1% year-over-year to $2.25 billion from $1.95 billion •    Reacting to news that Microsoft (NASDAQ:MSFT) is considering a bid for Yahoo (NASDAQ:YHOO), shares of the company gained 3.30% to close at $25.89 •    Share prices of lightning manufacture Acuity Brands Inc. (NYSE:AYI) increased 11.67% to close at $37.73 after the company posted a profitable fourth quarter results •    Share prices Lufkin Industries Inc. (NASDAQ:LUFK) fell 8.79% during the early hours of the days trade after the company lowered its outlook for the third-quarter •    Analysts at Citigroup upgraded shares of Acorda Therapeutics (NASDAQ:ACOR) to &#8220;Buy&#8221; rating from &#8220;Hold&#8221; rating •    Analysts at Citi ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/acor-company-news-for-october-6-2011-corporate-summary/84712/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gains &#8211; Earnings Miss Estimates</title>
		<link>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628</link>
		<comments>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628#comments</comments>
		<pubDate>Thu, 04 Aug 2011 15:47:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80628</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during the quarter led to the surge in the company’s earnings. Revenues Quarterly revenues shot up 52.4% to $65.3 million, driven primarily by strong Ampyra sales. However, revenues marginally missed the Zacks Consensus Estimate of $67 million. Second quarter revenues comprised $62.9 million (up 55.3%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $51.8 million, reflecting a year-over-year increase of 85%. Ampyra, aimed at improving walking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Company News for August 2, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/02/acor-company-news-for-august-2-2011-corporate-summary/80405</link>
		<comments>http://www.stockbloghub.com/2011/08/02/acor-company-news-for-august-2-2011-corporate-summary/80405#comments</comments>
		<pubDate>Tue, 02 Aug 2011 21:23:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[JAZZ]]></category>
		<category><![CDATA[Jazz Pharmaceuticals Inc]]></category>
		<category><![CDATA[KEG]]></category>
		<category><![CDATA[Key Energy Services Inc]]></category>
		<category><![CDATA[Old National BanCorporation]]></category>
		<category><![CDATA[ONB]]></category>
		<category><![CDATA[PAET]]></category>
		<category><![CDATA[PAETEC Holding Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80405</guid>
		<description><![CDATA[•    Allstate Corporation (NYSE:ALL) reported Q2 loss of $1.23, lower than the Zacks Consensus Estimate of $1.53 per share. Revenues for the quarter increased by 5% year-over-year to $8.08 billion, exceeding the Zacks Consensus Estimate of $6.91 billion•    Auxilium Pharmaceuticals (NASDAQ:AUXL) posted a Q2 loss of $0.11 per share, less than the analysts&#8217; estimate for a loss of $0.19 per share. Revenues for the quarter increased 30.5% year-over-year to $65.9 million •    Humana (NYSE:HUM) reported Q2 EPS of $2.50, beating the Zacks Consensus Estimate of $2.07 per share. Revenues increased 8.1% year-over-year to $9.28 billion, lower than the Zacks Consensus Estimate of $9.32 billion •    Acorda Therapeutics (NASDAQ:ACOR) posted Q2 EPS of $0.01. Revenues for the pharma company rose 52.6% year-over-year to $65.3 million •    Share prices of Old National ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/02/acor-company-news-for-august-2-2011-corporate-summary/80405/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Inks Deal with Medtronic</title>
		<link>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511</link>
		<comments>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511#comments</comments>
		<pubDate>Wed, 06 Jul 2011 21:18:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[SCI]]></category>
		<category><![CDATA[Service Corporation International]]></category>
		<category><![CDATA[TBI]]></category>
		<category><![CDATA[TrueBlue Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78511</guid>
		<description><![CDATA[Acorda Therapeutics, Inc. (ACOR) recently entered into a licensing agreement with Medtronic, Inc. (MDT) for AC105. The company acquired worldwide development and commercialization rights to AC105. The Candidate – AC105 Acorda intends to study AC105 as an acute treatment for patients who have suffered neurological trauma, such as spinal cord injury (SCI) and traumatic brain injury (TBI). The candidate has demonstrated neuroprotective properties and improvement of locomotor function in SCI and cognitive function in TBI when therapy was initiated within four hours of injury in preclinical studies. Medtronic has evaluated the candidate in phase I studies conducted with healthy volunteers. Acorda intends to initially conduct phase II studies with the candidate for SCI. Other studies may subsequently be conducted for central nervous system indications like TBI and stroke. AC105 enjoys ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra</title>
		<link>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214</link>
		<comments>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:45:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76214</guid>
		<description><![CDATA[Acorda Therapeutics, Inc. (ACOR) recently reported an analysis of data on Ampyra (dalfampridine) at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The analysis demonstrated improvements in walking ability of patients on Ampyra as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12). The analysis comprised data from a phase II trial and two phase III trials of Ampyra. These data were a part of Acorda’s new drug application (NDA) submission to the US Food and Drug Administration (FDA) for the approval of the drug. At the CMSC meeting, another set of study data on Ampyra called – UTI (urinary tract infection) Incidence among MS Patients Treated with Dalfampridine 10 mg Twice Daily – was also presented. As the name suggests, the study evaluated the incidence ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Company News for May 23, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/23/acor-company-news-for-may-23-2011-corporate-summary/74692</link>
		<comments>http://www.stockbloghub.com/2011/05/23/acor-company-news-for-may-23-2011-corporate-summary/74692#comments</comments>
		<pubDate>Mon, 23 May 2011 17:58:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[AES]]></category>
		<category><![CDATA[AKAM]]></category>
		<category><![CDATA[Akamai Technologies Inc.]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Barnes & Noble Inc.]]></category>
		<category><![CDATA[BKS]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[Gap Inc.]]></category>
		<category><![CDATA[GPS]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[The AES Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74692</guid>
		<description><![CDATA[•    Shares of Morgan Stanley (NYSE:MS) were guided lower after FrontPoint Partners LLC decided to close some of its hedge funds in which Morgan Stanley holds a minor stake by this month •    After a regulatory filing disclosed that the chief scientist of Akamai Technologies Inc. (NASDAQ:AKAM) had purchased 50,000 shares of its stock, the company’s shares jumped 5.1% •    Salesforce.com Inc. (NYSE:CRM) reported first quarter fiscal 2012 adjusted net income of 6 cents per share, a penny ahead of the Zacks Consensus Estimate. Revenues for the quarter were $504.4 million, up 33.9% from $376.8 million in the year-ago quarter. Results exceeded the company’s own guidance range of $480.0 million to $482.0 million and the Zacks Consensus Estimate of $483.0 million •    Bank of America (NYSE:BAC) has decided to sell ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/23/acor-company-news-for-may-23-2011-corporate-summary/74692/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermesto Buy Elan Unit for $960 Million</title>
		<link>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637</link>
		<comments>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637#comments</comments>
		<pubDate>Mon, 09 May 2011 22:55:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[HBC]]></category>
		<category><![CDATA[HSBC HLDGS PLC ADS]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73637</guid>
		<description><![CDATA[Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately $960 million. The merged entity will be known as Alkermes plc and will be headquartered in Dublin, Ireland. The deal, expected to boost Alkermes’ cash earnings immediately following its closure, has been cleared by the board of directors of both companies. Morgan Stanley &#38; Co. (MS) and HSBC (HBC) have agreed to finance up to $450 million of the deal through term loans to Alkermes. Per the terms of the deal, Alkermes will make a cash payment of $500 million apart from giving Elan 31.9 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations</title>
		<link>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532</link>
		<comments>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532#comments</comments>
		<pubDate>Sun, 08 May 2011 15:50:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73532</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) posted a loss of 2 cents per share for the first quarter of fiscal 2011, compared with a loss of 56 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 18 cents per share. Despite increased revenues, higher operating expenses resulted in a loss during the quarter. Quarterly Details Quarterly revenues saw a whopping 245.3% increase to reach $61.3 million, with Ampyra sales exceeding expectations. However, revenues missed the Zacks Consensus Estimate of $65 million. Fourth quarter revenues comprised $58.9 million (up 282.9%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $46.8 million. Ampyra, aimed at improving walking speed in multiple sclerosis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Analyst Reduces Share Rating to Neutral</title>
		<link>http://www.stockbloghub.com/2010/10/03/biib-biogen-idec-analyst-reduces-share-rating-to-neutral/53721</link>
		<comments>http://www.stockbloghub.com/2010/10/03/biib-biogen-idec-analyst-reduces-share-rating-to-neutral/53721#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:07:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53721</guid>
		<description><![CDATA[We recently downgraded Biogen Idec, Inc. (BIIB) to Neutral from our previous Outperform recommendation. Biogen is one of the world’s largest biotechnology companies. Its main areas of focus include neurology, oncology, hemophilia and immunology. Products such as Avonex (for multiple sclerosis), Rituxan (for non-Hodgkin’s lymphoma), and Tysabri (for multiple sclerosis) currently drive the top line. Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex, posted sales of $2,322.9 million, up 5.5%, in 2009. We expect Avonex to continue contributing significantly to the top-line thanks to price increases, focused marketing effort and positive clinical data. Meanwhile, Tysabri, the company’s second MS product, continued to see an increase ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/biib-biogen-idec-analyst-reduces-share-rating-to-neutral/53721/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec and Abbott Laboratories Begin Patient Enrollment in Study</title>
		<link>http://www.stockbloghub.com/2010/05/26/biib-biogen-idec-and-abbott-laboratories-begin-patient-enrollment-in-study/38543</link>
		<comments>http://www.stockbloghub.com/2010/05/26/biib-biogen-idec-and-abbott-laboratories-begin-patient-enrollment-in-study/38543#comments</comments>
		<pubDate>Wed, 26 May 2010 23:23:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38543</guid>
		<description><![CDATA[Biogen Idec (BIIB) and Abbott (ABT) recently announced that they have started enrolling patients for their phase III study with daclizumab. The study– DECIDE, will evaluate the efficacy and safety of daclizumab in patients suffering from relapsing-remitting multiple sclerosis (RRMS). The candidate will be compared with Biogen’s Avonex. With the enrolment of the first patient, Biogen will have to make a $30 million milestone payment to Abbott. Abbott gained access to daclizumab with its recent acquisition of Facet Biotech. The worldwide, randomized, double-blind, active-comparator phase III study will be conducted with about 1,500 RRMS patients across 28 countries. A once-monthly subcutaneous formulation of daclizumab will be evaluated as a monotherapy. Daclizumab is currently undergoing another study as well. The candidate is in a phase IIb registration-enabling study (SELECT), which is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/26/biib-biogen-idec-and-abbott-laboratories-begin-patient-enrollment-in-study/38543/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics&#8217; Multiple Sclerosis Drug Gets FDA Clearance</title>
		<link>http://www.stockbloghub.com/2010/01/25/acor-acorda-therapeutics-multiple-sclerosis-drug-gets-fda-clearance/25972</link>
		<comments>http://www.stockbloghub.com/2010/01/25/acor-acorda-therapeutics-multiple-sclerosis-drug-gets-fda-clearance/25972#comments</comments>
		<pubDate>Tue, 26 Jan 2010 04:36:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25972</guid>
		<description><![CDATA[Recently, Acorda Therapeutics Inc. (ACOR) announced that the U.S. Food and Drug Administration (FDA) has cleared its oral drug Ampyra (dalfampridine) which aims to improve walking speed in patients suffering from multiple sclerosis (MS). The company expects to launch the drug in the United States in March 2010. Ampyra is the first drug to get FDA approval for treating walking impairment in MS patients. Ampyra, previously known as Fampridine-SR, is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), which was previously referred to as fampridine. The drug enjoys orphan drug designation from the U.S. agency, thereby providing it with seven years of market exclusivity. Ampyra will be manufactured under a license and supply agreement with Elan Pharma International Limited, a subsidiary of Elan Corporation, plc (ELN). However, Ampyra will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/25/acor-acorda-therapeutics-multiple-sclerosis-drug-gets-fda-clearance/25972/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen&#8217;s Tysabri is a Blockbuster!</title>
		<link>http://www.stockbloghub.com/2010/01/13/biib-biogens-tysabri-is-a-blockbuster/24853</link>
		<comments>http://www.stockbloghub.com/2010/01/13/biib-biogens-tysabri-is-a-blockbuster/24853#comments</comments>
		<pubDate>Wed, 13 Jan 2010 17:40:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24853</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) recently announced that its multiple sclerosis (MS) drug Tysabri achieved blockbuster status in 2009. Sales of the drug, which is approved for relapsing forms of MS in the US and for relapsing-remitting MS in the EU, achieved $1 billion in sales in 2009. Tysabri is marketed by Biogen in collaboration with Elan Corp. (ELN). In addition to reporting Tysabri sales, Biogen provided an update on other products and pipeline candidates. The company stated that it intends to grow Avonex and Rituxan sales through lifecycle management. Meanwhile, Biogen recently submitted a marketing authorization application seeking approval from the European Medicines Agency for Fampridine prolonged release tablets. The company is seeking approval for the use of the candidate to improve the walking ability of adult patients with MS. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/biib-biogens-tysabri-is-a-blockbuster/24853/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FACT) Facet Biotech Rejects Biogen Idec Again</title>
		<link>http://www.stockbloghub.com/2009/12/11/fact-facet-biotech-rejects-biogen-idec-again/22636</link>
		<comments>http://www.stockbloghub.com/2009/12/11/fact-facet-biotech-rejects-biogen-idec-again/22636#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:27:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22636</guid>
		<description><![CDATA[Facet Biotech Corp. (FACT) once again rejected Biogen Idec Inc.’s (BIIB) intention to acquire all the outstanding shares of Facet common stock stating that the revised offer is inadequate and not in the best interests of Facet Biotech&#8217;s stockholders. Earlier this month, Biogen had come back with a revised offer of $17.50 per share (up from the previous offer of $14.50) and said that this is its “best and final&#8221; offer. The offer represents a 21% premium over the previous offer and a premium of approximately 98% over the closing price of Facet’s common stock on September 3, 2009, the day before Biogen announced its proposal to acquire all the outstanding shares of Facet. The offer is scheduled to expire at 12:00 midnight, New York City time, on Dec 16, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/fact-facet-biotech-rejects-biogen-idec-again/22636/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Big Pharma and Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146</link>
		<comments>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:57:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2009/11/08/acor-acorda-therapeutics-bull-of-the-day/19836</link>
		<comments>http://www.stockbloghub.com/2009/11/08/acor-acorda-therapeutics-bull-of-the-day/19836#comments</comments>
		<pubDate>Mon, 09 Nov 2009 03:22:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19836</guid>
		<description><![CDATA[Acorda Therapeutics (ACOR) is one of the more interesting biotechnology companies under our coverage. The company&#8217;s key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010. Outside the U.S., Acorda has partnered with Biogen Idec under very favorable terms. Fampridine-SR has blockbuster potential worldwide in our view. Plus, the company is extremely well-capitalized with over $290 million in cash, and management has commercial experience with current approved product Zanaflex. These are among the best fundamentals in all of biotech. We reiterate our Outperform rating on the stock. Zacks Investment Research View original at: Zacks.com News Feed]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/acor-acorda-therapeutics-bull-of-the-day/19836/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Reports Higher Earnings</title>
		<link>http://www.stockbloghub.com/2009/10/20/biib-biogen-reports-higher-earnings/18245</link>
		<comments>http://www.stockbloghub.com/2009/10/20/biib-biogen-reports-higher-earnings/18245#comments</comments>
		<pubDate>Tue, 20 Oct 2009 22:38:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18245</guid>
		<description><![CDATA[Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to $1.12 billion, with Tysabri being the primary growth driver. Tysabri sales came in at $207 million, up 21% from the prior period. The company estimates that as of the end of September 2009, about 46,200 patients were on commercial and clinical Tysabri therapy worldwide. This represents an increase from the 43,300 patients reported by the company in the second quarter of 2009. Tysabri is an important growth driver and we expect the product, which is partnered with Elan (ELN), to cross $1 billion in worldwide sales in 2009. Meanwhile, Biogen’s lead multiple sclerosis (MS) product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/biib-biogen-reports-higher-earnings/18245/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation</title>
		<link>http://www.stockbloghub.com/2009/10/20/biib-biogen-extends-hostile-bid-for-facet-biotech-corporation/18157</link>
		<comments>http://www.stockbloghub.com/2009/10/20/biib-biogen-extends-hostile-bid-for-facet-biotech-corporation/18157#comments</comments>
		<pubDate>Tue, 20 Oct 2009 20:06:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18157</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) extended its tender offer for the acquisition of all of the outstanding shares of Facet Biotech Corporation (FACT) to December 16, 2009. The offer was previously set to expire on October 19, 2009. As of October 15, 2009, about 28,336 shares of Facet Biotech stock have been tendered. Earlier this month, Facet’s board of directors unanimously recommended that its stockholders should reject Biogen’s tender offer under which the company is seeking to acquire for $14.50 per share in cash. The board determined that the offer is inadequate and not in the best interests of the stockholders. As a reminder, Biogen launched a hostile bid in September to acquire Facet by taking its offer directly to Facet’s shareholders. The deal is valued at approximately $356 million. Biogen ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/biib-biogen-extends-hostile-bid-for-facet-biotech-corporation/18157/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer</title>
		<link>http://www.stockbloghub.com/2009/10/12/fact-facet-investors-urged-to-deny-biogen-idec-tender-offer/17383</link>
		<comments>http://www.stockbloghub.com/2009/10/12/fact-facet-investors-urged-to-deny-biogen-idec-tender-offer/17383#comments</comments>
		<pubDate>Mon, 12 Oct 2009 17:02:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17383</guid>
		<description><![CDATA[In line with expectations, Facet Biotech Corporation’s (FACT) board of directors unanimously recommended that its stockholders should reject the unsolicited conditional tender offer from Biogen Idec Inc. (BIIB), which is seeking to acquire all the outstanding shares of Facet Biotech common stock for $14.50 per share in cash. The board has determined that the offer is inadequate and not in the best interests of the company’s stockholders. As a reminder, Biogen launched a hostile bid in September to acquire Facet for $14.50 per share by taking its offer directly to Facet’s shareholders. The deal is valued at approximately $356 million. Biogen had initially approached Facet with an offer of $15 per share on Aug 17, 2009. However, Facet did not accept the offer as the company doubted its benefit for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/12/fact-facet-investors-urged-to-deny-biogen-idec-tender-offer/17383/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech</title>
		<link>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986</link>
		<comments>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986#comments</comments>
		<pubDate>Thu, 24 Sep 2009 19:57:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15986</guid>
		<description><![CDATA[After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash balance is less than Biogen’s offer price. The deal is valued at approximately $356 million. The tender offer will expire at 12:00 midnight, ET, on Oct. 19, 2009. As a reminder, Biogen had initially approached Facet with an offer of $15 per share on Aug. 17, 2009. However, Facet did not accept the offer as the company believed that it was not in the best interests of its shareholders. Soon thereafter, Facet entered into a collaboration with Trubion Pharmaceuticals (TRBN), a move that was criticized by Biogen. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

